THIS week’s edition of the
Repatriation General Hospital
Pharmacy E-Bulletin gives an
overview of factors influencing
anticoagulation with rivaroxaban.
Rivaroxaban is an oral direct
factor Xa inhibitor in advanced
clinical development for the
prevention and treatment of
thromboembolic disorders, with a
half-life of 6-7 hours.
The bulletin is available for
download at no charge from
chris.alderman@health.sa.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Aug 10
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.